So, we now need to exactly identify the signals between neurons that tell one neuron to drop their use and take on a neighboring neuron's use! That could then make neuroplasticity repeatable on demand. If your doctor and hospital aren't pushing for further research on this; THEY ARE COMPLETELY FUCKING INCOMPENT!
Do you prefer your doctor, hospital and board of director's incompetence NOT KNOWING? OR NOT DOING?
Pharmacological regulation of adult brain neuroplasticity: Synergistic roles of neuropeptide signaling, psychedelics, and synaptic modulators
Introduction
Neuroplasticity is the brain's capability for structural and functional modification in response to environmental stimuli, learning, and injury. It has thus become a keystone concept in framing an understanding both of healthy neurological function and the processes of recovery following disease or trauma (Marzola et al., 2023). While initially research identified childhood and adolescence as critical periods of heightened plasticity, contemporary studies show adult brains retain significant, albeit diminished plastic potential, thereby implicating neuroplasticity in the ongoing processes of cognition, emotional regulation, and adaptive behavior throughout the lifespan (Marzola et al., 2023; Sharma et al., 2013).
The underlying mechanisms of neuroplasticity involve a suite of molecular and cellular processes, including synaptic remodeling, dendritic spine formation, extracellular matrix turnover, homeostatic scaling of neural circuits, and activity-dependent regulation of gene expression (Pozo and Goda, 2010; Wang et al., 2025). Synaptic plasticity, characterized by phenomena such as long-term potentiation (LTP), long-term depression (LTD), and spike-timing-dependent plasticity (STDP), represents a critical substrate for adaptive changes in neuronal connectivity (Appelbaum et al., 2023; Shokr and Eladawy, 2025). These mechanisms support learning and memory and provide a basis for functional recovery after neurological insult. Aberrations in neuroplastic dynamics have also been implicated in a spectrum of psychiatric and neurodegenerative disorders, ranging from major depressive disorder and schizophrenia to Alzheimer's, Parkinson's disease, and stroke (Appelbaum et al., 2023; Alshahrani et al., 2025).
Pharmacological approaches to enhance neuroplasticity in the adult brain are rapidly evolving, with great implications for clinical and scientific investigations (Toader et al., 2025; Pathak et al., 2025). These generally include agents targeting synaptic modulators, such as N-methyl d-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and gamma amino butyric acid (GABA) receptor agonists and antagonists; compounds targeting neuropeptide systems, including brain-derived neurotrophic factor (BDNF), oxytocin, and vasopressin; and a growing class of psychedelic substances, such as psilocybin, lysergic acid diethylamide (LSD), ketamine, and 3,4-methylenedioxymethamphetamine (MDMA) (Toader et al., 2025; Pathak et al., 2025; Rosas-Sánchez et al., 2024).
Within the pharmacology of neuroplasticity, synaptic modulators, mainly those affecting glutamatergic neurotransmission, play a central role (Chakraborty et al., 2023). A remarkable rapid-acting antidepressant action has been shown for NMDA receptor antagonists such as ketamine, together with clear evidence of increased synaptic connectivity and spine density in preclinical models (Krystal et al., 2024; Jóźwiak-BeRbenista et al., 2024). Simultaneously, agents targeting AMPA receptors and modulators of GABAergic systems contribute to fine-tuned adjustments in the balance between excitation and inhibition, enabling adaptive circuit remodeling (Thompson, 2024).
Classic psychedelics, such as psilocybin and LSD, and non-classic agents like ketamine and MDMA, function predominantly through the serotonin 5-HT2A receptor to initiate cascades promoting both structural and functional neuroplasticity (Cameron et al., 2023). Contemporary research underlines their capacity to induce spinogenesis, synaptogenesis, and increased expression of plasticity-related genes within hours of administration, with long-lasting changes observed in neural network dynamics (Cameron et al., 2023). Currently, these substances are under active investigation for the treatment of refractory depression, post-traumatic stress disorder (PTSD), substance use disorders, and neurodegeneration, with early results indicating sustained improvements in cognitive and affective domains (Cameron et al., 2023).
In parallel, neuropeptide systems-most notably those involving BDNF-have been identified as important regulators of neuronal growth and synaptic function in response to stressors (Toader et al., 2025). Pharmacological augmentation of neuropeptide function-either directly through mimetic agents, or indirectly via treatment strategies that upregulate their signaling pathways-represents a second, promising strategy for improving neuroplasticity and functional outcome following injury or disease (Dergunova et al., 2023).
Non-invasive brain stimulation techniques such as Transcranial Magnetic Stimulation (TMS) and transcranial direct current stimulation (tDCS) synergize with pharmacological treatments to cause region-specific neuroplastic adaptations that enhance rehabilitation outcomes (Portaro et al., 2025). Nonetheless, the convergence of molecular neuroscience, pharmacology, and clinical innovation promises a transformative impact on the management of neuropsychiatric and neurodegenerative disorders, leveraging the adult brain's inherent, though limited, capacity for plastic adaptation.
In all, pharmacological approaches to enhancing neuroplasticity in the adult brain-from synaptic modulators and psychedelics to neuropeptide systems-are rewriting the expectations for recovery, resilience, and adaptive cognition across the life course. Further research will continue to refine these interventions and establish the extent to which they enable durable neuroadaptive change.
Access through your organization
Check access to the full text by signing in through your organization.
Section snippets
Synaptic remodeling and plasticity
Synaptic plasticity is a process believed to be the primary means of dynamic change in synaptic strength and connectivity in the adult brain, which underlies learning, memory, and recovery after neurological insult (Dennis et al., 2013). At its most fundamental level, synaptic plasticity involves activity-dependent strengthening LTP and weakening LTD of synapses, processes most well described in the hippocampal CA1 region-a structure critical for the encoding and retrieval of episodic memory (
Molecular pathways and the crosstalk between receptors
Synaptic plasticity is orchestrated by intricate crosstalk between NMDA, AMPA, and GABA receptor systems, seamlessly integrating excitatory and inhibitory signals through a web of intracellular signaling pathways, synaptic scaffolding proteins, and dynamic regulatory mechanisms (Chapman et al., 2022). This interplay enables precise modifications of synaptic strength and connectivity, a process fundamental to learning, memory consolidation, adaptive emotional responses, and the recovery from
NMDA receptor modulators: gatekeepers of plasticity
The NMDA receptors occupy a pivotal role in excitatory synaptic transmission and neuroplasticity, serving as molecular gatekeepers for the adaptive changes that underpin learning, memory, and behavioral flexibility (Smith, 2025). Structurally, NMDA receptors are heterotetrameric complexes composed of two obligatory NR1 subunits and a combination of NR2 (A-D) and sometimes NR3 subunits. The specific NR2 subunit composition determines the receptor's kinetic and pharmacological properties, which
Activation of serotonin 5-HT2A receptors and downstream plasticity pathways
Classic psychedelics primarily exert their effects through agonism at the serotonin 5-HT2A receptor, setting in motion unique signaling cascades that drive both acute and enduring neuroplastic changes (Table 2) (Cameron et al., 2023). Preclinical studies reveal that psychedelic drugs such as psilocybin, LSD, and DMT stimulate 5-HT2A receptors not only at the plasma membrane but also intracellularly, inciting growth-promoting molecular programs distinct from those engaged by endogenous serotonin
BDNF signaling: central mediator of structural and functional neuroplasticity
BDNF is the most abundant growth factor in the mammalian brain and a pivotal regulator of neuroplasticity, supporting neuronal survival, differentiation, and synaptic adaptation (Toader et al., 2025). BDNF exerts its effects primarily through the TrkB receptor, stimulating a cascade that involves NMDA and AMPA receptor activation, intracellular Ca2+ influx, and subsequent gene transcription vital to LTP, synaptogenesis, and dendritic remodeling (Toader et al., 2025). Experimental disruption of
Limitations and future directions
The advancement of pharmacological agents designed to enhance neuroplasticity is reshaping the therapeutic landscape for a range of neurological and psychiatric disorders, but these innovations also raise profound safety, ethical, and regulatory challenges (Gazerani, 2025). Chief among safety concerns are the unpredictable and sometimes adverse effects associated with many neuroplasticity-promoting drugs, particularly classical psychedelics like psilocybin, LSD, and MDMA, as well as
Conclusions
In conclusion, the ongoing exploration of pharmacological strategies to enhance neuroplasticity in the adult brain reveals significant promise for the treatment of psychiatric, neurological, and cognitive disorders. Growing evidence demonstrates that synaptic modulators, psychedelics, and neuropeptide-based interventions can rapidly and robustly induce both structural and functional plasticity in cortical and subcortical networks, leading to improvements in mood, cognition, and behavioral
No comments:
Post a Comment